Together, our findings suggest that combined blockade of IL-6 and CTLA-4 can regress pancreatic tumors via a potentially unique mechanism by imparting CD4+ and CD8+ T cell–mediated antitumor immunity. Here, IL6 is linked to pancreatic neoplasm.